Current role of imaging techniques in cardiac amyloidosis

Maurer, 2017, Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis, Circulation., 135, 1357, 10.1161/CIRCULATIONAHA.116.024438 Eanes, 1968, X-ray diffraction studies on amyloid filaments, J Histochem Cytochem., 16, 673, 10.1177/16.11.673 Maleszewski, 2015, Cardiac amyloidosis: pathology, nomenclature, and typing, Cardiovasc Pathol., 24, 343, 10.1016/j.carpath.2015.07.008 Benson, 2018, Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee, Amyloid., 25, 215, 10.1080/13506129.2018.1549825 Garcia-Pavia, 2021, Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases, Eur Heart J., 42, 1554, 10.1093/eurheartj/ehab072 Lachmann, 2006, Systemic amyloidosis, Curr Opin Pharmacol., 6, 214, 10.1016/j.coph.2005.10.005 Aimo, 2018, Therapies for cardiac light chain amyloidosis: an update, Int J Cardiol., 271, 152, 10.1016/j.ijcard.2018.05.018 Falk, 2016, AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy, J Am Coll Cardiol., 68, 1323, 10.1016/j.jacc.2016.06.053 Fontana, 2015, Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study, Radiology., 277, 388, 10.1148/radiol.2015141744 Martinez-Naharro, 2018, Cardiac amyloidosis, Clin Med (Lond)., 18, s30, 10.7861/clinmedicine.18-2-s30 Wechalekar, 2016, Systemic amyloidosis, Lancet., 387, 2641, 10.1016/S0140-6736(15)01274-X Bart, 2020, Amyloid cardiomyopathy, Heart Lung Circ., 29, 575, 10.1016/j.hlc.2019.11.019 González-López, 2015, Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction, Eur Heart J., 36, 2585, 10.1093/eurheartj/ehv338 Ruberg, 2012, Transthyretin (TTR) cardiac amyloidosis, Circulation., 126, 1286, 10.1161/CIRCULATIONAHA.111.078915 Chacko, 2019, Cardiac amyloidosis: updates in imaging, Curr Cardiol Rep., 21, 108, 10.1007/s11886-019-1180-2 Coelho, 2013, THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis, Curr Med Res Opin, 29, 63, 10.1185/03007995.2012.754348 Ruiz Pizarro, 2022, Fabry cardiomyopathy: parametric mapping adds even more, Rev Esp Cardiol (Engl Ed), S1885-5857, 00125 Gertz, 2015, Diagnosis, prognosis, and therapy of transthyretin amyloidosis, J Am Coll Cardiol., 66, 2451, 10.1016/j.jacc.2015.09.075 Cyrille, 2014, Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis, Am J Cardiol., 114, 1089, 10.1016/j.amjcard.2014.07.026 Carroll, 1982, Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation, Am J Cardiol., 49, 9, 10.1016/0002-9149(82)90270-3 Quarta, 2014, Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis, Circulation., 129, 1840, 10.1161/CIRCULATIONAHA.113.006242 Mussinelli, 2013, Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis, Ann Noninvasive Electrocardiol., 18, 271, 10.1111/anec.12036 Senapati, 2016, Prognostic implication of relative regional strain ratio in cardiac amyloidosis, Heart., 102, 748, 10.1136/heartjnl-2015-308657 Nitsche, 2021, Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis, J Am Coll Cardiol., 77, 128, 10.1016/j.jacc.2020.11.006 Feng, 2007, Intracardiac thrombosis and embolism in patients with cardiac amyloidosis, Circulation., 116, 2420, 10.1161/CIRCULATIONAHA.107.697763 Boldrini, 2020, Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis, JACC Cardiovasc Imaging., 13, 909, 10.1016/j.jcmg.2019.10.011 Maceira, 2005, Cardiovascular magnetic resonance in cardiac amyloidosis, Circulation., 111, 186, 10.1161/01.CIR.0000152819.97857.9D Austin, 2009, Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis, JACC Cardiovasc Imaging., 2, 1369, 10.1016/j.jcmg.2009.08.008 Fontana, 2015, Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis, Circulation., 132, 1570, 10.1161/CIRCULATIONAHA.115.016567 Claudia, 2019, Miocardiopatías infiltrativas. Aporte de la resonancia cardiaca, Revista Colombiana Cardiologia., 26 Fontana, 2016, Staging cardiac amyloidosis with CMR: understanding the different phenotypes, JACC Cardiovasc Imaging, 9, 1278, 10.1016/j.jcmg.2016.02.035 Fontana, 2014, Native T1 mapping in transthyretin amyloidosis, JACC Cardiovasc Imaging., 7, 157, 10.1016/j.jcmg.2013.10.008 Chacko, 2021, Cardiac magnetic resonance-derived extracellular volume mapping for the quantification of hepatic and splenic amyloid, Circ Cardiovasc Imaging., 10.1161/CIRCIMAGING.121.012506 Hazenberg, 2006, Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis, Am J Med., 119, 355, 10.1016/j.amjmed.2005.08.043 Thavendiranathan, 2012, Improved detection of myocardial involvement in acute inflammatory cardiomyopathies using T2 mapping, Circ Cardiovasc Imaging., 5, 102, 10.1161/CIRCIMAGING.111.967836 Ferreira, 2014, Myocardial tissue characterization by magnetic resonance imaging: novel applications of T1 and T2 mapping, J Thorac Imaging., 29, 147, 10.1097/RTI.0000000000000077 Kotecha, 2018, Myocardial edema and prognosis in amyloidosis, J Am Coll Cardiol., 71, 2919, 10.1016/j.jacc.2018.03.536 Falk, 1983, Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis, Am J Cardiol., 51, 826, 10.1016/S0002-9149(83)80140-4 Perugini, 2005, Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy, J Am Coll Cardiol., 46, 1076, 10.1016/j.jacc.2005.05.073 Hutt, 2017, Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid, Eur Heart J Cardiovasc Imaging., 18, 1344, 10.1093/ehjci/jew325 Gillmore, 2016, Nonbiopsy diagnosis of cardiac transthyretin amyloidosis, Circulation., 133, 2404, 10.1161/CIRCULATIONAHA.116.021612 Saleem, 2021, Hereditary apolipoprotein A-I-associated cardiac amyloidosis: importance of endomyocardial biopsy when suspicion remains high, JACC Case Rep, 3, 1032, 10.1016/j.jaccas.2021.02.016 Antoni, 2013, In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET, J Nucl Med., 54, 213, 10.2967/jnumed.111.102053 Lee, 2015, 11C-Pittsburgh B PET imaging in cardiac amyloidosis, JACC Cardiovasc Imaging., 8, 50, 10.1016/j.jcmg.2014.09.018 Dorbala, 2014, Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography, Eur J Nucl Med Mol Imaging., 41, 1652, 10.1007/s00259-014-2787-6 Wagner, 2018, Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds, Eur J Nucl Med Mol Imaging., 45, 1129, 10.1007/s00259-018-3995-2 Osborne, 2015, A routine PET/CT protocol with streamlined calculations for assessing cardiac amyloidosis using (18)F-Florbetapir, Front Cardiovasc Med., 2, 23, 10.3389/fcvm.2015.00023 Law, 2017, Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: a pilot study, Amyloid., 24, 162, 10.1080/13506129.2017.1281120 Kim, 2020, Cardiac amyloidosis imaging with amyloid positron emission tomography: a systematic review and meta-analysis, J Nucl Cardiol., 27, 123, 10.1007/s12350-018-1365-x Genovesi, 2021, [18F]-Florbetaben PET/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions, JACC Cardiovasc Imaging., 14, 246, 10.1016/j.jcmg.2020.05.031 Ezawa, 2018, Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging, Eur J Nucl Med Mol Imaging., 45, 452, 10.1007/s00259-017-3814-1